Xencor, Inc. (NASDAQ:XNCR) major shareholder John S. Stafford III acquired 50,000 shares of the business’s stock in a transaction on Thursday, November 2nd. The stock was purchased at an average cost of $19.58 per share, with a total value of $979,000.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.10. Xencor had a negative net margin of 121.04% and a negative return on equity of 13.79%. The firm had revenue of $13.34 million during the quarter, compared to analysts’ expectations of $8.15 million.

TRADEMARK VIOLATION WARNING: This report was reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/11/02/john-s-stafford-iii-purchases-50000-shares-of-xencor-inc-xncr-stock.html.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Alps Advisors Inc. lifted its stake in shares of Xencor by 0.3% in the second quarter. Alps Advisors Inc. now owns 20,102 shares of the biopharmaceutical company’s stock valued at $424,000 after purchasing an additional 52 shares during the period. Falcon Point Capital LLC increased its holdings in Xencor by 0.5% during the 2nd quarter. Falcon Point Capital LLC now owns 29,082 shares of the biopharmaceutical company’s stock valued at $614,000 after acquiring an additional 156 shares in the last quarter. Parametric Portfolio Associates LLC increased its holdings in Xencor by 0.6% during the 1st quarter. Parametric Portfolio Associates LLC now owns 36,253 shares of the biopharmaceutical company’s stock valued at $867,000 after acquiring an additional 209 shares in the last quarter. Legal & General Group Plc increased its holdings in Xencor by 4.5% during the 2nd quarter. Legal & General Group Plc now owns 8,978 shares of the biopharmaceutical company’s stock valued at $189,000 after acquiring an additional 385 shares in the last quarter. Finally, Cornerstone Capital Management Holdings LLC. increased its holdings in Xencor by 2.3% during the 2nd quarter. Cornerstone Capital Management Holdings LLC. now owns 23,321 shares of the biopharmaceutical company’s stock valued at $492,000 after acquiring an additional 521 shares in the last quarter. Hedge funds and other institutional investors own 76.81% of the company’s stock.

A number of research analysts have weighed in on XNCR shares. ValuEngine cut shares of Xencor from a “hold” rating to a “sell” rating in a report on Monday, October 23rd. Canaccord Genuity set a $36.00 price objective on shares of Xencor and gave the company a “buy” rating in a report on Monday, October 23rd. BidaskClub cut shares of Xencor from a “hold” rating to a “sell” rating in a report on Monday, August 14th. Finally, Zacks Investment Research cut shares of Xencor from a “hold” rating to a “sell” rating in a report on Friday, August 11th. Three equities research analysts have rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $28.00.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Insider Buying and Selling by Quarter for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.